Heidi Cuthbert - Author on Grafa
All
Delcath Systems reports preliminary full-year 2025 revenue of $85.2M
Delcath Systems (NASDAQ:DCTH), an interventional oncology company specializing in treatments for primary and metastatic liver cancers, announced preliminary unaudited financial results and business updates for the fourth quarter and full year ended December 31, 2025.
Cartesian Therapeutics advances Descartes-08 pipeline with Phase 3 enrollment on track and new IND clearance
Cartesian Therapeutics (NASDAQ:RNAC) provided an update on its Descartes-08 program, a first-in-class autologous mRNA-engineered CAR-T cell therapy targeting B-cell maturation antigen (BCMA) for the treatment of autoimmune diseases, and outlined key 2026 priorities.
Perspective Therapeutics reports 39% response rate in breakthrough alpha-radiopharmaceutical trial
Perspective Therapeutics (NYSE:CATX) reported updated interim safety and efficacy data from its ongoing Phase 1/2a trial of [212Pb]VMT-α-NET, a targeted alpha-particle radiopharmaceutical for the treatment of neuroendocrine tumors, with a data cut-off of December 10, 2025.






-640x358.jpg&w=1200&q=75)



-640x358.jpg&w=1200&q=75)